OPINION The role of amino acid profiles in diabetes risk assessment
INTRODUCTION
The obesity and diabetes epidemic is rapidly increasing in both developed and developing countries. Due to the global shift toward a lifestyle of Western eating habits and inactivity, and, in some regions, because of the aging of the adult population, the prevalence of diabetes is expected to increase worldwide, especially in Asian populations [1, 2] . Diabetes not only burdens patients with numerous complications, such as cardiovascular disease, nephropathy, neuropathy, and retinopathy but also steadily increases healthcare costs. In recent years, metabolomics has made remarkable progress in consistently providing novel biomarkers. Among these biomarkers, plasma-free amino acid profiles have produced an overwhelming number of promising results. Diabetes risk assessment is a primary area of interest in this field. For example, several metabolites, including branched-chain amino acids (BCAAs) and aromatic amino acids (AAAs), have been associated with visceral obesity [3] and insulin resistance [4] [5] [6] . A longitudinal analysis confirmed that plasma-free amino acid concentrations could predict the development of diabetes, for example, the Framingham Offspring Study over a 12-year period revealed that BCAA and AAA levels are significantly related to the future development of diabetes [7] . A subsequent study confirmed that these BCAAs and AAAs are associated with the development of cardiovascular disease [8] . This review discusses recent progress in plasma amino acid profiling, with a particular focus on the early assessment of the risk of developing diabetes and the normalization of plasma-free amino acid profiles by various interventions. Recent developments that increase the utility of amino acid profiling technology are also described.
EARLY RISK ASSESSMENT WITH PLASMA-FREE AMINO ACID PROFILING
Early risk assessment and early interventions are critical for preventive medicine. The early introduction of lifestyle modifications to individuals who are at higher risk of developing lifestyle-related diseases is important. Because macrovascular complications of the insulin-resistant state precede the onset of hyperglycemia and actually begin during the prediabetic phase, this condition must be addressed even if the fasting blood glucose or hemoglobin A1c levels are lower than the established clinical criteria. Plasma-free amino acid concentrations, which are altered by visceral fat accumulation [3] and insulin resistance [4] [5] [6] , have been identified as potential biomarkers for early detection. Several recent studies have revealed plasma-free amino acid alterations in study participants with normal glucose tolerance, a prediabetes condition. The associations of plasma-free amino acid profiles with the type and degree of obesity and with glucose and insulin regulation were examined in study participants with normal glucose tolerance [9 && ]. The study reported that visceral obesity was associated with higher levels of BCAAs, lysine, tryptophan, cystine, and glutamate but lower levels of asparagine, citrulline, glutamine, glycine, and serine, even in study participants with normal glucose tolerance. After adjustments for age and sex, visceral fat area was positively correlated with tryptophan and glutamate levels, whereas the visceral and subcutaneous fat areas were negatively correlated with citrulline, glutamine, and glycine levels. In addition, glucose and insulin dysregulation were positively correlated with valine, glutamate, and tyrosine levels but negatively correlated with citrulline, glutamine, and glycine levels. These results are consistent with former reports on study participants including impaired glucose tolerance and diabetes [3] , suggesting that patients with early prediabetes already have specific alterations in amino acid metabolism. However, a recent study indicated that among study participants without diabetes, the BCAA level was positively correlated with muscle volume, fasting blood glucose levels, fasting immunoreactive insulin levels, and the homeostasis model assessment of b-cell function and was negatively associated with the homeostasis model assessment of insulin resistance [10] . Further detailed examinations are necessary to clarify the associations between plasma-free amino acids, muscle volume, and insulin dysregulations in nondiabetic study participants.
Recently, we published a cohort study of 2984 study participants following the development of lifestyle-related diseases in the relatively near future [11 && ]. We found that plasma-free amino acid alterations can be used to predict the development of diabetes within a 4-year period, even after adjustments for commonly accepted risk factors, such as age, sex, BMI, fasting plasma glucose level, homeostasis model assessment of insulin resistance, waist circumference, blood pressure (BP), and lipid variables. Furthermore, the plasma-free amino acid levels could also predict the 4-year development of metabolic syndrome, dyslipidemia, or hypertension after adjusting for commonly accepted risk factors. A multivariate regression model for evaluating amino acid concentrations, termed 'AminoIndex technology', was then used to compress the multidimensional information from amino acid profiles into a single score to maximize the differences between case and control populations. Although it is still investigational, the resulting amino acid model provided robust predictions of the 4-year risk of developing diabetes, metabolic syndrome, dyslipidemia, and hypertension in a generally healthy population ( Fig. 1) . Recently, clinical evidence has shown the importance of plasma-free amino acids profiles for understanding poor metabolic health conditions throughout the world [7,11 && ,12-15] . The next step would be to better understand the detailed features and limitations of plasma-free amino acid profiling as a part of clinical routines.
DO THE ALTERED PLASMA-FREE AMINO ACID PROFILES NORMALIZE?
Do the altered plasma-free amino acid profiles revert to normal when the risk of developing diseases
KEY POINTS
The association between conditions with higher risks for developing diabetes and altered plasma-free amino acid profiles even in early stages has mostly been established as evidence has accumulated throughout the world.
These altered plasma-free amino acid concentrations are reversed by several types of interventions that improve insulin sensitivity, including nutritional, drug, and surgical interventions.
To develop clinical applications for routine use, the procedures for measuring amino acids are being standardized and automated.
decreases? Several intervention studies have answered 'Yes'. Some reported the reversal of plasma-free amino acid profiles in morbidly obese patients following surgery [16] [17] [18] . One study showed that weight loss by Roux-en-Y gastric bypass (RYGB) surgery caused a decrease in plasma BCAA concentrations and that this decrease was associated with skeletal muscle insulin sensitivity [18] . In a different study, the reduction in circulating levels of BCAA caused by RYGB was compared with the change caused by a very low-calorie diet in morbidly obese patients (approximately 45 kg/m 2 ); both RYGB and diet interventions normalized the circulating BCAA levels, and RYGB had a larger BCAA normalization effect [16, 17] .
Although these studies focused on morbidly obese patients, a recently published study reported plasma-free amino acid normalization in patients with metabolic syndrome at lower BMIs [19 & ]. In this study, the average BMI was approximately 29 kg/m 2 , and patients who had diagnostic criteria for metabolic syndrome were enrolled in a 3-month diet and exercise intervention. The plasma-free amino acid concentrations and metabolic variables were compared between those who lost more than 3% of their initial body weight and those who lost less than 3%. The weight loss induced by the intervention normalized the plasma-free amino acid profiles even in these study participants with the early stages of lifestyle-related diseases. In addition, the plasmafree amino acid improvements were associated with improvements in BP and in triglyceride and hemoglobin A1c levels. Another study examined the effect of weight loss diets on long-term changes in circulating amino acid concentrations [20 && ]. Plasma-free amino acid profiles were measured over a 2-year period in overweight or obese participants of two randomized, dietary intervention, weight loss trials (Preventing Overweight Using Novel Dietary Strategies Trial) and (Dietary Intervention Randomized Controlled Trial). The dietary intervention consistently lowered the concentrations of most amino acids, including BCAAs and AAAs, in both trials. In addition, the reductions in alanine and the tyrosine were significantly associated with improved insulin resistance, independent of weight loss, in both trials.
Another recent study confirmed the effect of 3-month insulin sensitizer therapy with metformin and pioglitazone on the plasma-free amino acid profiles in a double-blind trial [21 & ]. The study confirmed that on average, insulin sensitizer therapy reduced fasting plasma amino acid and amino acid metabolite concentrations in overweight/obese adults with fasting hyperglycemia or previously untreated diabetes. Taken together, the results indicate that plasma-free amino acid profiling has potential as a biomarker for both assessing diabetes risk and monitoring the effects of strategies (nutritional, drug, or surgical interventions) designed to lower that risk.
DOES THE DISTURBANCE OF PLASMA-FREE AMINO ACIDS CAUSE INSULIN RESISTANCE OR ARE THESE AMINO ACIDS MERELY BIOMARKERS?
Does the altered plasma-free amino acid pattern contribute to insulin resistance or does insulin resistance cause plasma-free amino acid alterations? The role of increased plasma BCAA levels in modifying insulin sensitivity has been a topic of heavy debate. Some rodent studies or cellular studies suggest that BCAA supplementation promotes insulin resistance via the stimulation of mammalian target of rapamycin complex 1 and S6 kinase and the phosphorylation of the insulin receptor substrates 1 and 2 [22] . However, a number of clinical studies have suggested that BCAA supplementation or BCAA-rich diets are beneficial [23] , with positive effects on body weight regulation, muscle protein synthesis, and glucose homeostasis as well as increased satiety that facilitates body weight loss.
Recently, the first clinical study to directly evaluate the effects of short-term exposure to increased BCAA levels on plasma glucose turnover was published [24 & ]. In this study, generally healthy study participants were randomly assigned to receive either insulin infused during the second half of a 6-h intravenous infusion of a BCAA mixture to stimulate plasma glucose turnover or insulin under the same conditions but without BCAA infusion. Plasma glucose turnover was measured prior to and during the insulin infusion. Insulin infusion suppressed the endogenous glucose production and increased the whole-body glucose disposal rate, but there were no differences between the control and BCAA groups. This was the first study to directly confirm that the short-term elevation of plasma BCAA concentrations does not affect the insulin sensitivity and glucose metabolism in humans. Another recent experiment confirmed the effect of an insulin sensitizer on plasma-free amino acid normalization [21 & ]. The research clarified that the improvement in insulin sensitivity induced by the insulin sensitizer normalized the plasma-free amino acid concentrations. These findings suggest that insulin resistance per se is responsible for the elevation of BCAA concentrations rather than BCAA elevations causing insulin resistance.
Given these results, why do plasma amino acid levels vary depending on the degree of accumulation of visceral fat and insulin resistance? Interestingly, although the concentrations of most amino acids increase under these conditions, the concentrations of a few amino acids, such as glycine, serine, and citrulline, decrease. The overall elevation of circulating amino acids is thought to be caused by the decreased uptake and decreased utilization of amino acids by muscles because of insulin resistance [23] . In addition, several distinctive modifications of the amino acid metabolism pathway are believed to affect the concentration of each amino acid.
For these amino acid changes, specific mechanisms that dysregulate BCAA concentrations have been intensively studied. The abundance of enzymes involved in the oxidation of BCAAs in muscles is reduced in insulin-resistant individuals [25] ; furthermore, a specific role of visceral adipose tissue in BCAA metabolism has become evident. The accumulation of adipose tissue, which is accompanied by the release of adipocytokines and free fatty acids, changes the systemic conditions such that the inflammatory tone increases. The invasion of macrophages triggers early events in obesityinduced insulin resistance [26] , and it is thought that enhanced inflammation affects BCAA metabolism. Two enzymes, mitochondrial branchedchain aminotransferase and branched-chain keto acid dehydrogenase (BCKDH), begin the transamination of all three BCAAs, which are thereafter decarboxylated and dehydrated. Animal and clinical studies have demonstrated the reduced expression and activity of mitochondrial branched-chain aminotransferase and BCKDH in adipose tissue in obese and diabetic conditions [27, 28] . The reduced expression of BCAA catabolic genes downstream of BCKDH was also shown in insulin-resistant study participants and was associated with the increased expression of the inflammatory cytokine TNFa and a decrease in the gene expression of adiponectin [29] . Furthermore, at the cellular level, treating adipocytes with proinflammatory cytokines decreased the degradation of leucine; this finding emphasizes the role of inflammatory cytokines in BCAA metabolism in adipocytes [30 & ]. Adiponectin, an adipocytokine, was also demonstrated to affect BCAA oxidation in mitochondria in an experiment using adiponectin knockout mice [31] . The adiponectin knockout mice fed a high-fat diet had decreased BCKDH activity in their muscles, and the decrease was reversed upon treatment with adiponectin. In line with this evidence, a clinical study with diabetic patients found a strong negative correlation between plasma BCAA and adiponectin levels [32] . Such observations can explain the negative correlation between plasma BCAA levels and insulin sensitivity, whereby increased BCAA concentrations are secondary to the decreased ability to metabolize BCAAs. Although the mechanism underlying the altered BCAA circulation is well studied, other types of plasma-free amino acids, such as tyrosine, phenylalanine, alanine, glycine, serine, and tryptophan, are poorly investigated. It is believed that these alterations are also caused by a combination of insulin resistance-induced accelerated protein breakdown in muscle and changes in the gluconeogenesis and lipogenesis set points in the liver; however, further studies are required (Fig. 2) .
Studies have consistently shown that higher levels of dietary BCAA intake are associated with a lower prevalence of obesity [33] and a decreased risk of diabetes [34 && ]. Given these findings, the negative correlation between circulating BCAA levels and insulin sensitivity may be paradoxical. Future studies to examine the physiological meaning of circulating amino acid alterations under these conditions are warranted.
OTHER APPLICATIONS OF AMINO ACID PROFILING
In addition to the assessment of diabetes risk, several other possibilities for plasma amino acid profiling have been proposed. Research focusing on the relationship between gestational diabetes and plasma metabolites, including amino acids, has been reported [35] [36] [37] [38] [39] . This research suggests amino acid changes related to the development of gestational diabetes. Cardiometabolic traits are another research topic, and metabolite profiles across multiple have been associated with various cardiometabolic traits [40] [41] [42] . One study investigated the metabolic signatures of obesity and the related cardiometabolic traits in the Framingham Offspring cohort participants. Metabolite profiling has highlighted the considerable overlap with abdominal adiposity, insulin resistance, and dyslipidemia but not with fasting glucose or BP traits [42] .
Our recent pilot study examined whether the altered plasma-free amino acid profiles in study participants with metabolic syndrome are related to the effectiveness of diet and exercise interventions [19 & ]. In this study, the weight loss group (those who lost more than 3% of their initial body weight) and the nonweight loss group (those who lost less than 3%) were stratified at the end of the 3-month program. We demonstrated that the baseline plasma-free amino acid concentrations of the study participants in the nonweight loss group were significantly lower than those in the weight loss group, and no clear differences were found in the other metabolic variables. If the baseline plasmafree amino acid profiles differ in ways that predict the responsiveness to a weight loss program, the profile could be a useful biomarker to determine whether the intervention program is suited to a participant. Further verifications of our results are needed.
Although most amino acid profiling studies focus on the fasting condition, some studies measure amino acid profiling at a different time [43] [44] [45] . One study examined amino acid responses to a standardized meal challenge [45] . The study examined the association of amino acid responses with normal fasting glucose, newly diagnosed impaired fasting glycemia, and newly diagnosed diabetes. Intriguingly, for almost all amino acids, a lower response was observed in the diabetes group than in the normal fasting glucose group, indicating that these measures may also be potential biomarkers for diabetes. Determining the fields that could benefit from amino acid profiling could be another research question. 2 . Schematic of the mechanism for altered plasma-free amino acid concentrations. Plasma-free amino acid concentrations in obesity/insulin resistance conditions are thought to be affected by a combination of insulin resistanceinduced accelerated protein break down in muscles and changes in the gluconeogenesis and lipogenesis set point in the liver.
In particular for BCAA dysregulation, the specific role of visceral adipose tissue, which has a reduced capacity to metabolize BCAA because of insulin resistance, has become evident. AAA, aromatic amino acid; BCAA, branched-chain amino acid; CVD, cardiovascular disease; Gly, glycine; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; Ser, serine.
TECHNOLOGICAL DEVELOPMENTS IN AMINO ACID PROFILING
To translate basic metabolomics research into clinical applications for routine use, the standardization of the procedures and high speed and automated measurements are necessary. The basic blood sample collection and sample management methods have been examined [46] . Blood samples were subjected to a number of different treatments; hemolysis, temperature after blood collection, time from blood collection to cooling, the influence of platelets, long-term storage conditions, and repeated freeze-thaw cycles, and changes in the concentrations of 22 amino acids were determined. Four factors were confirmed to be critical for stable measurements: hemolysis, temperature immediately after blood collection, time from collection to cooling, and long-term storage temperature.
Recently, there were several [47
&&
,48] advances in the measurement of amino acids. One study focused on shortening the measurement time. The researchers described a simple method using capillary electrophoresis to separate and quantify BCAA in less than 3 min [49] . Progress has occurred in the automation of analytical systems for analyzing amino acids using HPLC/electrospray ionization mass spectrometry to avoid human operation error and to improve reproducibility. A new instrument [the UF-Amino Station (Shimadzu Corporation, Kyoto, Japan)] for amino acid analysis that allows an automated precolumn derivatization using a HPLC/electrospray ionization mass spectrometry system has been developed [47 && ]. After the optimization of the entire analytical process from blood collection to amino acid analysis, the analytical method was validated. This system could separate 38 types of physiological amino acids in only 8 min. The developed method was validated for 21 major types of free amino acids in human plasma within acceptable ranges for analysis. The precision was measured as repeatability, intermediate reproducibility, and reproducibility. In this developed method, the repeatability was within 4.0%, the intermediate reproducibility was within 6.2%, and the reproducibility was within 7.0%. This new method was compared with a conventional ion exchange chromatography, and the square correlation coefficient was over 0.96 and the slope ranged between 0.91 and 1.04. The intercept ranged between À5.2 and 11.6. Furthermore, with this method, reference intervals for plasma-free amino acids were examined in 7685 Japanese study participants. The full list of plasma-free amino acid reference intervals is found in this report [50] . Reference intervals for biochemical variables are routinely used in the field of clinical laboratory testing and thus, the reference intervals for plasma-free amino acids are critical for the routine use of this information. A total of 1890 reference individuals who were presumed to be healthy on the basis of various exclusion criteria were selected from 7685 study participants; the lower limit of the reference intervals for the plasma amino acid concentrations was set at the 2.5th percentile, and the upper limit was set at the 97.5th percentile. The study revealed that most amino acid concentrations were more closely related to sex than to age or BMI. The preferable reference intervals were suggested to be stratified by sex when the background factors of sex, age, and BMI are considered. Gathering this type of basic information is of considerable importance, especially if we consider the routine clinical use of this methodology.
CONCLUSION
The association between conditions with higher risks for developing diabetes and altered plasma-free amino acid profiles, even in the early stages, has mostly been established, and these altered profiles are reversed by nutritional, drug, or surgical interventions that improve insulin sensitivity. Although the mechanism to elevate plasma BCAA levels has been intensively studied, mechanism for altering other amino acid concentrations has room for investigation. The next steps should pave the way to utilizing plasma amino acid profiling in clinical diagnoses. Standardization of the procedures is important, and automation and high-speed measurements of amino acid concentrations are required. This is the first study to confirm the effect of weight loss diets on long-term changes in plasma-free amino acids and the relation of these changes with weight loss and improvement in insulin resistance in two large dietary intervention trials over 2 years of intervention. Intervention diets consistently lowered most of the amino acid concentrations, including BCAAs and AAAs, in both trials. 21.
